149 related articles for article (PubMed ID: 11317528)
1. [Tamoxifen--"golden standard" in the treatment of patients with early breast cancer].
Semiglazov VF; Kostetskaia TV
Vopr Onkol; 2001; 47(1):108-12. PubMed ID: 11317528
[No Abstract] [Full Text] [Related]
2. Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
Du XL
J Natl Cancer Inst; 2003 May; 95(9):683; author reply 684-5. PubMed ID: 12734321
[No Abstract] [Full Text] [Related]
3. Does c-erbB2/HER2 overexpression predict adjuvant tamoxifen failure in patients with early breast cancer?
Hu JC; Mokbel K
Eur J Surg Oncol; 2001 Jun; 27(4):335-7. PubMed ID: 11417974
[No Abstract] [Full Text] [Related]
4. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
Van Poznak CH; Hayes DF
J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
[No Abstract] [Full Text] [Related]
5. Tamoxifen prevention of breast cancer: an instance of the fingerpost.
Lippman SM; Brown PH
J Natl Cancer Inst; 1999 Nov; 91(21):1809-19. PubMed ID: 10547388
[No Abstract] [Full Text] [Related]
6. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
7. Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
Di Leo A; Buyse M
J Clin Oncol; 2002 Apr; 20(7):1954-5. PubMed ID: 11919262
[No Abstract] [Full Text] [Related]
8. [Antiestrogenic agents for treatment of advanced breast cancers].
Kimura M
Nihon Rinsho; 2000 Apr; 58 Suppl():311-6. PubMed ID: 11026011
[No Abstract] [Full Text] [Related]
9. Is fulvestrant more effective than tamoxifen for treating ER-positive breast cancer in postmenopausal women?
Raina V
Nat Clin Pract Oncol; 2004 Nov; 1(1):20-1. PubMed ID: 16264793
[No Abstract] [Full Text] [Related]
10. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
Gamucci T
Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
[No Abstract] [Full Text] [Related]
11. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: the example of clinical studies].
Giannessi PG
Suppl Tumori; 2004; 3(4):S73-4. PubMed ID: 15206218
[No Abstract] [Full Text] [Related]
12. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
Angiolini C
Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
[No Abstract] [Full Text] [Related]
13. Targeting breast cancer with hormonal treatment options.
Mellington TE; Fields MM
Nurse Pract; 2008 May; 33(5):17-22; quiz 22-3. PubMed ID: 18458623
[No Abstract] [Full Text] [Related]
14. [The ATAC study on adjuvants in breast cancer].
Bravi S
Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
[No Abstract] [Full Text] [Related]
15. Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
Narasimhadevara R; Pollak MN; Foulkes WD
J Natl Cancer Inst; 2003 Jun; 95(12):917; author reply 918-9. PubMed ID: 12813177
[No Abstract] [Full Text] [Related]
16. Adjuvant therapy for all patients with breast cancer?
Lippman ME; Hayes DF
J Natl Cancer Inst; 2001 Jan; 93(2):80-2. PubMed ID: 11208870
[No Abstract] [Full Text] [Related]
17. Tamoxifen: an enduring star.
Veronesi U; Maisonneuve P; Decensi A
J Natl Cancer Inst; 2007 Feb; 99(4):258-60. PubMed ID: 17312297
[No Abstract] [Full Text] [Related]
18. [Current issues in adjuvant hormone therapy of breast cancer].
Semiglazov VF; Semiglazov VV
Vopr Onkol; 2003; 49(6):771-5. PubMed ID: 14976929
[No Abstract] [Full Text] [Related]
19. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen, mammographic density, and breast cancer prevention.
Boyd NF
J Natl Cancer Inst; 2011 May; 103(9):704-5. PubMed ID: 21487099
[No Abstract] [Full Text] [Related]
[Next] [New Search]
